Hyperthermic intraperitoneal chemotherapy in colorectal cancer.

Oliver M FisherChris BrownJesus EsquivelStein G LarsenWinston LiauwNayef A AlzahraniDavid L MorrisVahan KepenekianIsabelle SourrouilleFrédéric Dumont Jean-Jacques TuechCécilia CeribelliBéranger DoussotOlivia SgarburaMohammed AlhosniFrancois QuenetOlivier GlehenPeter H Cashinnull null

Published in: BJS open (2024)

Oxaliplatin-based HIPEC provided better outcomes compared to mitomycin-based HIPEC. High-dose mitomycin-HIPEC was similar to oxaliplatin-HIPEC. The 90-day mortality difference favours the oxaliplatin-HIPEC group. A trend for dose-response between low- and high-dose HIPEC was reported.

Keyphrases

high dose
low dose
squamous cell carcinoma
risk factors
cardiovascular events
metabolic syndrome
cardiovascular disease
coronary artery disease
insulin resistance